Utilization of the Ingenuity Health Medication Monitoring Program at Center for Health Care Services Roberto Jimenez, M.D. Denise Canchola, D.N.P.

Slides:



Advertisements
Similar presentations
Role of the Pharmacist in Collaborative Care for Mental Health and Addiction Treatment in Medically Underserved Appalachia Sarah T. Melton, PharmD,BCPP,CGP.
Advertisements

Improving Dementia Care and Reducing Unnecessary Use of Antipsychotic Medications in Nursing Homes Alice Bonner, PhD, RN Division of Nursing Homes Center.
OVERVIEW OF DDS ACS HCBS MEDICAID WAIVER. Medicaid Regular state plan Medicaid pays for doctor appointments, hospital expenses, medicine, therapy and.
Best Practices in Mental Health Services in Nursing Homes Steve Bartels, MD, MS President, American Association for Geriatric Psychiatry.
BACKGROUND: ANTIPSYCHOTIC TREATMENT OF YOUNG CHILDREN.
PROVIDENCE CENTRALIA HOSPITAL EMERGENCY DEPARTMENT COMMUNITY ACCESS PROJECT Cindy Mayo, Chief Executive.
The Biggest Loser Challenge: A Pill for Atypical Antipsychotic Induced-Weight Gain? Julie A. Dopheide, Pharm.D., BCPP Associate Professor of Clinical Pharmacy,
Arkansas Children’s Behavioral Health Care Commission AR DHS Division of Medical Services Pharmacy Program Laurence H. Miller, M.D., Senior Psychiatrist.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September-October 2007.
Implementation of Pain Programs within Coordinated Care Organizations
HOSPITAL BASED INPATIENT PSYCHIATRIC SERVICES (HBIPS) MEASURE SET Kathy Wonderly RN, BSPA, CPHQ Performance Improvement Coordinator Developed: February,
1 Mental Health and Substance Abuse Services Division Association of Substance Abuse Providers Mike Maples October 5, 2011.
Texas Suicide Safe Care: Zero Suicides in Texas (ZEST) Creating a statewide comprehensive suicide safe care system.
Increase the Proportion of Metabolic Syndrome Screening In Adults with Severe Mental Illness receiving "atypical” second generation antipsychotics.
Healthcare Reform The “Affordable Care Act” How Will It Affect Substance Abuse Care?
HIT Adoption and Opportunity: Perspectives from the Primary Care Safety Net Presented by Greta J. Stewart, MPH, CAE Oklahoma Primary Care Association HRSA/BPHC.
1 Governor’s Office of Health Policy and Finance MaineCare Pharmacy Initiatives.
Use of Atypical Antipsychotic Drugs by Children and Adolescents in the United States: A Retrospective Cohort Study Lesley H. Curtis, PhD Center for Clinical.
Antipsychotic Utilization: Oregon State Medicaid Ann M. Hamer, PharmD BCPP This presentation was made possible by a grant from the State Attorney General.
WHAT IS THE EVIDENCE ON EFFECTIVENESS OF ANTIPSYCHOTICS IN PERSONS WITH DEMENTIA? 1.
Click to edit Master subtitle style Aetna Behavioral Health Depression Initiatives June 2006.
Affective Disorders. Who can tell me how many people suffer in America from bipolar disorder?” About 2 million people suffer and that is starting at 18.
Use of Antipsychotic Drugs in Dementia Josepha A. Cheong, MD University of Florida Departments of Psychiatry and Neurology Chief, Division of Geriatric.
They deserve personalized treatment Your patients are unique.
Urine Drug Monitoring: Indiana Council of Community Mental Health Centers Jerry Vaccaro, M.D. President, Ingenuity Health October 15, 2015.
Teresa Hudson, PharmD Center for Mental Healthcare and Outcomes Research South Central Mental Illness Research Education and Clinical Center.
Reducing Preventable Emergency Room Visits 1. An Opportunity Redirecting care to the most appropriate setting protects patient safety and ensures payment.
Levels of Review of Research and Quality Improvement Walter Kraft, MD Associate Director, Office of Human Subjects Protection Department of Pharmacology.
for MHD & Therapeutics is proud to present And Now Here Is The Host... Dr. Schilling.
Audit of psychotropic medication prescribing in EMI nursing homes in Monmouthshire Dr Pauline Ruth Dr Rui Zheng Dr Arpita Chakraborty Dr Usman Mansoor.
Prescription Medication Working Group Co-Chairs Katherine Murray and Tom Werner March 14, 2007.
NICE guidance Generalised Anxiety Disorder Alex Hill.
Antipsychotic Medications: Prevalence of Inappropriate Use, Polypharmacy, and Non-Adherence Nancy G. Pham, PharmD; Lisa Le, MS; Karen M. Stockl, PharmD;
ASCO’s Quality Training Program Project Title: Improving oral chemotherapy fulfillment processes and implementation of a pharmacist- managed oral chemotherapy.
August 22, 2012 at 11:30 a.m. Audio: (888) , participant code # Press *6 to mute and unmute your phone.
© Copyright 2011, Pearson Education, Inc. All rights reserved. Psychotropic Medication: Overview 1.0 CEU Presented by Dr. Jeremy Burd MD Medical Director.
Dementia and Medication Considerations
Medication therapy management
Medication Assisted Treatment
Current Concepts in Pain Management
SANDCASTLE FAMILY PRACTICE
Designated Infection Control Office
Wireless Access SSID: cwag2017
Jessica E. Bates, Pharm.D. PGY-1 Pharmacy Resident
Addressing Partial-Response or Non-Response
Research Questions Does integration of behavioral health and primary care services, compared to simple co-location, improve patient-centered outcomes in.
Answers to Your Questions About Tardive Dyskinesia
Introduction to Clinical Pharmacy
Department of Health and Human Services Community Paramedicine
Brief Overview of Common Psychotropic Medications --and--
Batch Prescribing Repeat Dispensing
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Pharmacogenetic testing:
Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics Flavio Guzmán, MD.
Ten Pearls for Medication Assisted Treatment of Opiate Use Disorders
High Value Care– What’s Needed?
Community Centers of Texas
Accountable Health Communities Model
Long Acting Injectable Antipsychotic Medication
Certified Community Behavioral Health Clinic
Telemental Health Services in County Jails
Vision Transformative collaboration that fosters resilient self-sustaining Recovery Communities. Mission To develop and sustain measurable solutions that.
Certified Community Behavioral Health Clinics
Transforming Behavioral Healthcare
Medically assisted treatment
Texas Council Update Presented to: IDD DiRectors’ Consortium, September 10, 2015 Presented by: Erin E. Lawler, J.D., M.s. Director of IDD Services.
Medication Assisted Treatment of Opioid Use Disorder
Transforming the Delivery of Substance Use Disorder Treatment in States Update August 2019.
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Behavioral Health Identification, Treatment & Referral in Primary Care
Presentation transcript:

Utilization of the Ingenuity Health Medication Monitoring Program at Center for Health Care Services Roberto Jimenez, M.D. Denise Canchola, D.N.P.

Objectives: Define: Ingenuity Health Medication Monitoring. Learn how other centers in TX are using Ingenuity: CHCS Demonstrate Positive Patient Outcomes using Ingenuity. Discuss the Implementation Process and Costs

Clinical Goals for using Ingenuity: Objectively assess if patients are taking prescribed medications to allow for early intervention Identify possible use of non-prescribed medications, illicit drugs and alcohol that could interfere with treatment goals Detect whether genetic polymorphisms could be effecting medications prescribed to the patient. Reduce costs associated with relapse, hospitalization, unnecessary med changes, and unused prescriptions. Make clinical decisions with confidence.

Not the Goal of using Ingenuity.

THIS IS THE GOAL OF USING INGENUITY: Partnership with the patient, the provider and the community. WIN-WIN

Ingenuity Health’s Proprietary Antipsychotic Monitoring Method Detects Quantitative Levels of: Aripiprazole (Abilify®) Quetiapine (Seroquel®) Risperidone (Risperdal®) Lurasidone (Latuda®) Clozapine (Clozaril®) Haloperidol (Haldol®) Olanzapine (Zyprexa®) Paliperidone (Invega®) Ziprasidone (Geodon®)

Proprietary Reference Data for Identification of Partial Non-Adherence Reference Data for Adherence available for Abilify®, Risperdal®, Latuda® & Seroquel XR®. Normalized laboratory results are compared to a database of results from patients who have been clinically assessed as adherent, providing additional information about the likelihood of adherence to the patient’s prescribed total daily dose. . . Adherence reference ranges also available for Opioid medications, including Methadone.

Other Testing Available Detects Quantitative Levels of: Antidepressants Benzodiazepines Stimulants Sedatives/hypnotics Anti-Epileptics Opioids/synthetic opiates Illicit drugs Bath Salts, Synthetic Marijuana Alcohol EtG/EtS biomarkers

Center Analytics

Example Center Analytics: Abnormalities Found Ingenuity provides practice analytics to help Centers identify their areas of opportunity. * *

Example Center Analytics: Non-Prescribed Meds Found Ingenuity provides practice analytics to help Centers identify their areas of opportunity.

Determining a Monitoring Protocol

Clinical Assessment of Medication Compliance in Schizophrenia1 1Dolder, CR, et al., J Clin Psychopharmacology 2003;23(4): 389-399 11

Adherence diminishes over time: Keith, S., Kane, J. J Clin Psych. 2003;64(11): 1308-3015 12

Early Intervention Time to relapse after medication non-adherence: Average interval between discontinuation of meds and relapse of symptoms is 1 – 3 months.1 Routine monitoring for medication adherence offers providers the best opportunity for early intervention. 1Emsley, R, et al., BMC Psychiatry 2013; 13:50 13

Center for Health Care Services Monitoring Protocol First Six Months of Program: Initial assessment of all patients Ongoing Protocol: All new patients (either new to the Center or new to the provider) All walk-in appointments All post-hospitalization appointments Risk-based monitoring, as determined by the Provider, based on review of previous report and clinical assessment 14

Outcomes of a Routine Monitoring Program

Center for Health Care Services – Zarzamora 19% increase in patients with antipsychotic levels suggesting adherent use of their prescribed total daily dose over time. * * * Q1/Q2 2015 added monitoring of two additional antipsychotics

Center for Health Care Services – Packard 17% increase in patients with antipsychotic levels suggesting adherent use of their prescribed total daily dose over time. * * Q1 2015 added monitoring of two additional antipsychotics

Center for Health Care Services - Drexel 19% increase in patients with no abnormality detected (all prescribed drugs present and within range, and no non-prescribed drugs or illicits found). * Q1 2015 added monitoring of additional medications

Center for Health Care Services – Restoration Center 11% increase in patients with no abnormality detected (all prescribed drugs present and within range, and no non-prescribed drugs or illicits found).

Implementation and Costs

Texas Community Centers working with Ingenuity Pecan Valley Centers - Granbury EverHealth - Houston Currently in the Implementation process… Texas Panhandle Centers - Amarillo Hill Country MHDD - Kerrville Burke - Lufkin LifePath - McKinney Gulf Coast Centers - Galveston La Paz - San Antonio Center for Health Care Services - San Antonio Bluebonnet Trails Community Services - Round Rock MHMR Authority of Brazos Valley - Bryan Heart of Texas Region MHMR - Waco MHMR Services for the Concho Valley - San Angelo Permian Basin Community Centers for MHMR - Midland Tropical Texas Behavioral Health - Edinburg West Texas Centers - Big Spring Texoma – Sherman Coastal Plains Community Centers - Portland

Implementation Process All sample collection and shipping materials are supplied by Ingenuity Health. Collection process is noninvasive and performed during routine visits. Ingenuity team works closely with the Center to design and implement a simple workflow for the collection process. In most cases, Ingenuity provides a Specimen Processor onsite if Center staff is unable to perform the sample collection themselves. Ingenuity team provides on-site training and continual support for providers and staff.

Traditional Billing Policy Overview No cost to Clinic Covered 100% by Medicaid and Medicare and all billing is performed by Ingenuity Billed to private insurance, per patient’s plan Uninsured and Out-of-Network maximum bill $99, with sliding scale financial assistance available to all patients who qualify. Additional discounts beyond sliding scale may be available, based on patient need. $0 $25 $50 $75 23

Traditional Billing Policy in Action: Texas 24

Alternative Billing Policy Now Available Covered 100% by Medicaid and Medicare Billed to private insurance, per patient’s plan Uninsured patient testing billed to Center at maximum bill of $55, with sliding scale adjustment made based on the patients’ financial assessment. $0 $14 $28 $41 25

Ingenuity Health Contact Information Amy Varhely Mental Health Account Executive - Texas (512) 937-8184 amy.varhely@ingenuityhealth.com www.ingenuityhealth.com